234 related articles for article (PubMed ID: 34642088)
21. Development of nanoparticle vaccines utilizing designed Fc-binding homo-oligomers and RBD-Fc of SARS-CoV-2.
Liang Y; Xiao W; Peng Y; Zhang S; Dong J; Zhao J; Wang Y; Zhang M; Liu Z; Yu B
Antiviral Res; 2024 Jul; 227():105917. PubMed ID: 38782067
[TBL] [Abstract][Full Text] [Related]
22. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
[TBL] [Abstract][Full Text] [Related]
23. Effect of Fc Fusion on Folding and Immunogenicity of Middle East Respiratory Syndrome Coronavirus Spike Protein.
Chun J; Cho Y; Park KH; Choi H; Cho H; Lee HJ; Jang H; Kim KH; Oh YK; Kim YB
J Microbiol Biotechnol; 2019 May; 29(5):813-819. PubMed ID: 30982320
[TBL] [Abstract][Full Text] [Related]
24. Enhancement of immunogenicity and neutralizing responses against SARS-CoV-2 spike protein using the Fc fusion fragment.
Ehteshaminia Y; Jalali SF; Jadidi-Niaragh F; Enderami SE; Pagheh AS; Akbari E; Kenari SA; Hassannia H
Life Sci; 2023 May; 320():121525. PubMed ID: 36841470
[TBL] [Abstract][Full Text] [Related]
25. SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen.
Wang Y; Wang L; Cao H; Liu C
J Med Virol; 2021 Feb; 93(2):892-898. PubMed ID: 32691875
[TBL] [Abstract][Full Text] [Related]
26. Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice.
Wørzner K; Sheward DJ; Schmidt ST; Hanke L; Zimmermann J; McInerney G; Karlsson Hedestam GB; Murrell B; Christensen D; Pedersen GK
EBioMedicine; 2021 Jan; 63():103197. PubMed ID: 33422991
[TBL] [Abstract][Full Text] [Related]
27. Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice.
Sun S; He L; Zhao Z; Gu H; Fang X; Wang T; Yang X; Chen S; Deng Y; Li J; Zhao J; Li L; Li X; He P; Li G; Li H; Zhao Y; Gao C; Lang X; Wang X; Fei G; Li Y; Geng S; Gao Y; Wei W; Hu Z; Han G; Sun Y
Cell Mol Immunol; 2021 Apr; 18(4):1070-1073. PubMed ID: 33731916
[No Abstract] [Full Text] [Related]
28. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
29. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
30. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection.
Pérez P; Lázaro-Frías A; Zamora C; Sánchez-Cordón PJ; Astorgano D; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
Front Immunol; 2021; 12():824728. PubMed ID: 35154086
[TBL] [Abstract][Full Text] [Related]
31. RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge.
Wong TY; Russ BP; Lee KS; Miller OA; Kang J; Cooper M; Winters MT; Rodriguez-Aponte SA; Dalvie NC; Johnston RS; Rader NA; Wong ZY; Cyphert HA; Martinez I; Shaligram U; Batwal S; Lothe R; Chandrasekaran R; Nagar G; Rajurkar M; Rao H; Bevere JR; Barbier M; Love JC; Damron FH
mSphere; 2022 Aug; 7(4):e0024322. PubMed ID: 35968964
[TBL] [Abstract][Full Text] [Related]
32. Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein.
Li H; Zhang Y; Li D; Deng YQ; Xu H; Zhao C; Liu J; Wen D; Zhao J; Li Y; Wu Y; Liu S; Liu J; Hao J; Yuan F; Duo S; Qin CF; Zheng A
Signal Transduct Target Ther; 2021 Nov; 6(1):389. PubMed ID: 34759261
[TBL] [Abstract][Full Text] [Related]
33. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
[TBL] [Abstract][Full Text] [Related]
34. Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates.
Francica JR; Flynn BJ; Foulds KE; Noe AT; Werner AP; Moore IN; Gagne M; Johnston TS; Tucker C; Davis RL; Flach B; O'Connell S; Andrew SF; Lamb E; Flebbe DR; Nurmukhambetova ST; Donaldson MM; Todd JM; Zhu AL; Atyeo C; Fischinger S; Gorman MJ; Shin S; Edara VV; Floyd K; Lai L; Boyoglu-Barnum S; Van De Wetering R; Tylor A; McCarthy E; Lecouturier V; Ruiz S; Berry C; Tibbitts T; Andersen H; Cook A; Dodson A; Pessaint L; Van Ry A; Koutsoukos M; Gutzeit C; Teng IT; Zhou T; Li D; Haynes BF; Kwong PD; McDermott A; Lewis MG; Fu TM; Chicz R; van der Most R; Corbett KS; Suthar MS; Alter G; Roederer M; Sullivan NJ; Douek DC; Graham BS; Casimiro D; Seder RA
Sci Transl Med; 2021 Aug; 13(607):. PubMed ID: 34315825
[TBL] [Abstract][Full Text] [Related]
35. Immunization with RBD-P2 and N protects against SARS-CoV-2 in nonhuman primates.
Hong SH; Oh H; Park YW; Kwak HW; Oh EY; Park HJ; Kang KW; Kim G; Koo BS; Hwang EH; Baek SH; Park HJ; Lee YS; Bang YJ; Kim JY; Bae SH; Lee SJ; Seo KW; Kim H; Kwon T; Kim JH; Lee S; Kim E; Kim Y; Park JH; Park SI; Gonçalves M; Weon BM; Jeong H; Nam KT; Hwang KA; Kim J; Kim H; Lee SM; Hong JJ; Nam JH
Sci Adv; 2021 May; 7(22):. PubMed ID: 34049881
[TBL] [Abstract][Full Text] [Related]
36. Receptor-binding domain-based SARS-CoV-2 vaccine adjuvanted with cyclic di-adenosine monophosphate enhances humoral and cellular immunity in mice.
Germanó MJ; Giai C; Cargnelutti DE; Colombo MI; Blanco S; Konigheim B; Spinsanti L; Aguilar J; Gallego S; Valdez HA; Mackern-Oberti JP; Sanchez MV
J Med Virol; 2023 Feb; 95(2):e28584. PubMed ID: 36794675
[TBL] [Abstract][Full Text] [Related]
37. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
[TBL] [Abstract][Full Text] [Related]
38. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
39. Recombinant subunits of SARS-CoV-2 spike protein as vaccine candidates to elicit neutralizing antibodies.
Noorabad Ghahroodi F; Khalili S; Rasaee MJ
J Clin Lab Anal; 2022 May; 36(5):e24328. PubMed ID: 35349744
[TBL] [Abstract][Full Text] [Related]
40. Preclinical study of formulated recombinant nucleocapsid protein, the receptor binding domain of the spike protein, and truncated spike (S1) protein as vaccine candidates against COVID-19 in animal models.
Nazarian S; Olad G; Abdolhamidi R; Motamedi MJ; Kazemi R; Kordbacheh E; Felagari A; Olad H; Ahmadi A; Bahiraee A; Farahani P; Haghighi L; Hassani F; Hajhassan V; Nadi M; Sheikhi A; Salimian J; Amani J
Mol Immunol; 2022 Sep; 149():107-118. PubMed ID: 35802999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
